Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 4 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 4INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Carcinoma, Medullary 1Advanced Cancer 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Ranitidine × Clear all
NCT01287520 2019-02-25

A Study of LY2090314 in Patients With Advanced or Metastatic Cancer

Eli Lilly and Company

Phase 1 Completed
41 enrolled 28 charts

Advanced Cancer

NCT01539655 2017-05-02

Vandetanib

Sanofi

Phase 1 Completed
34 enrolled

Carcinoma, Medullary

NCT02441894 2017-01-24

PEGAZUS

Sanofi

Phase 4 Completed
21 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡